BioCentury
ARTICLE | Clinical News

Sumitomo's napabucasin unlikely to meet Phase III gastric cancer endpoint

July 7, 2017 8:49 PM UTC

The Boston Biomedical Inc. unit of Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506) said an interim analysis by a DSMB showed that napabucasin (BBI608, BB608) was unlikely to meet the primary endpoint of improving overall survival (OS) compared to placebo in the Phase III BRIGHTER trial to treat gastric or gastroesophageal junction cancer. The company is unblinding the trial, which compared twice-daily 480 mg oral napabucasin plus paclitaxel vs. paclitaxel alone in about 700 patients.

The double-blind, international trial's secondary endpoints include progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR) and safety...